Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 23Ovarian Neoplasms 18Neoplasm Metastasis 12Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Pancreatic Neoplasms 8Neoplasms 8Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma 2Lung Neoplasms 2Hodgkin Disease 2Fanconi Anemia, Complementation Group D1 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumours 2Advanced Solid Tumor 2Advanced Cancer 2Triple Negative Metastatic Breast Cancer 1Thymoma 1Thrombocytosis 1Solid Tumor 1

Interventions

talazoparib 1olaparib 1CX 5461 1BAY 2315497 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration Resistant Prostate Cancer (mCRPC) × olaparib × Clear all
NCT03874884 2025-05-14

LuPARP

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting
70 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡